Enter the e-mail address you used when you registered an account with IIR Energy.
A message will be sent to the E-Mail Address found in our records containing the associated username(s) as well as instructions for a password reset.
On Wednesday, September 21, drug giant Johnson & Johnson began Phase 3 clinical trials that will expand to an expected 60,000 volunteers in the U.S., South Africa and a half dozen South American countries. This is the largest trial to date of all COVID-19 vaccines in development.
Key features of the promising drug include the fact it does not need to be frozen and will likely only require one shot rather than two. Paul Stoffels, chief scientific officer at Johnson & Johnson, said the company may be able to determine the vaccine's safety and efficacy by the end of the year.
|Listen to Today's News||News Audio Library||Sync News Podcasts|
This article is free for all Registered Members.
Register Now! All Fields are Required...
Upgrade your Premium News Subscription to include all archived articles for only $160. Contact Member Services: 800-762-3361
All Members Receive the Following Free Resources: